QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
| Revenue (TTM) | $2.12B |
| Gross Profit (TTM) | $1.42B |
| EBITDA | $753.58M |
| Operating Margin | 27.80% |
| Return on Equity | 10.80% |
| Return on Assets | 5.68% |
| Revenue/Share (TTM) | $10.67 |
| Book Value | $16.83 |
| Price-to-Book | 3.13 |
| Price-to-Sales (TTM) | 4.91 |
| EV/Revenue | 5.41 |
| EV/EBITDA | 16.14 |
| Quarterly Earnings Growth (YoY) | -19.50% |
| Quarterly Revenue Growth (YoY) | 2.90% |
| Shares Outstanding | $206.50M |
| Float | $205.18M |
| % Insiders | 0.48% |
| % Institutions | 79.89% |
Volatility is currently contracting
Qiagen N.V. ( QGEN ) Shareholder/Analyst Call November 6, 2026 8:00 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Presentation Roland Sackers CFO, MD & Member of Management Board Good morning, good afternoon.
BALA CYNWYD, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. An estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the d.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities int.
QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi.
QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QGEN and any ticker you trade — then tracks every position and per-strategy win rate.
